Topic Name

Message

If ARUP Consult does not answer your test selection and interpretation questions, or if you would like to suggest ways to improve content or usability, please send a message to the Consult editorial staff.

Please do not include any patient-specific or personal health information (PHI) in your message.

Email Address

An email address is not required, but providing one allows the ARUP Consult editorial staff to respond directly. ARUP will only use your email address to respond to your feedback. See the ARUP privacy policy for more information regarding email use.

CAPTCHA

What code is in the image?

Enter the characters shown in the image.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drug Profile, Expanded Targeted Panels

3004833

Drug Profile, Expanded Targeted Panel by LC-MS/MS, Serum/Plasma 3004833

Method

Qualitative Liquid Chromatography-Tandem Mass Spectrometry

3005060

Drug Profile, Expanded Targeted Panel by LC-MS/MS, Urine 3005060

Method

Qualitative Liquid Chromatography-Tandem Mass Spectrometry

Use to detect drug exposure from among a targeted list of prescriptions, over-the-counter medications, and illicit drugs. Assays are for medical purposes only—not for forensic testing. Not recommended to determine medication compliance or to assess for undisclosed drug/substance use in the context of pain management, substance use disorder treatment, or any other pharmacotherapies involving controlled substances.

In 2020, more than 59 million people in the United States used illicit drugs. Furthermore, according to recent preliminary data from the Drug Abuse Warning Network (DAWN), opioids, methamphetamine, cannabis, and cocaine were among the top substances involved in emergency room visits. Other substances, such as prescription medications, are also common factors in the need for emergency medical care. For situations in which the identity or class of one or more drugs is unknown, multidrug analysis may be useful.

Test Interpretation

Sensitivity/Specificity

Analytic sensitivity: dependent on the cutoff concentrations for applicable analytes (127 analytes included). The concentration at which a drug or metabolite can be detected varies within a drug class. See below for a complete list of analytes and cutoff concentrations.
Specificity: high; mass spectrometric methodology.

Drug Class/Drug/Drug Metabolite	Drug Profile, Expanded Targeted Panels Cutoff Concentrations (ng/mL)
Anticoagulants
Apixaban	25
Rivaroxaban	25
Warfarin	100
Anticonvulsants
Brivaracetam	100
Carbamazepine	100
Carbamazepine-10,11-epoxide^a	100
Felbamate	100
Gabapentin	100
Lacosamide	100
Lamotrigine	100
Levetiracetam	100
Oxcarbazepine	—
10-hydroxycarbazepine^a	100
Pregabalin	100
Primidone	100
Rufinamide	100
Tiagabine	5
Topiramate	100
Zonisamide	100
Antidepressants
Amitriptyline	50
Nortriptyline^ab	50
Bupropion	5
Hydroxybupropion^a	5
Citalopram	5
N-desmethylcitalopram^a	5
Clomipramine	50
Desipramine	50
Doxepin	50
Desmethyldoxepin^a	50
Duloxetine	50
Fluoxetine	10
Norfluoxetine^a	50
Imipramine	50
N-desmethyltrimipramine^a	50
Mirtazapine	5
Paroxetine	10
Protriptyline	50
Sertraline	20
Trimipramine	50
Venlafaxine	10
O-desmethylvenlafaxine^a	10
Antidiabetics
Glimepiride	50
Glipizide	50
Glyburide	50
Antihistamines
Chlorpheniramine	100
Diphenhydramine	20
Doxylamine	50
Hydroxyzine	5
Pheniramine	5
Antipsychotics
Aripiprazole	50
Clozapine	10
N-desmethylclozapine^a	10
Haloperidol	5
Loxapine	5
Quetiapine	5
Risperidone	5
9-hydroxyrisperidone^a	5
Trazodone	50
Ziprasidone	5
Benzodiazepines
Alprazolam	5
Alpha-hydroxyalprazolam^a	20
Chlordiazepoxide	20
Clobazam	20
Clonazepam	5
7-aminoclonazepam^a	5
Diazepam	20
Nordiazepam^ab	20
Oxazepam^ab	20
Temazepam^ab	10
Lorazepam	20
Midazolam	5
Alpha-hydroxymidazolam^a	20
Zolpidem	5
Cardiac Medications
Atenolol	20
Atropine	5
Diltiazem	10
Disopyramide	100
Flecainide	50
Lidocaine	100
Metoprolol	5
Mexiletine	50
Propafenone	50
Propranolol	10
Sotalol	50
Verapamil	10
Norverapamil^a	10
Cough Suppressants
Dextromethorphan	5
Muscle Relaxants
Baclofen	20
Carisoprodol	100
Cyclobenzaprine	5
Meprobamate	100
Nicotine
Cotinine	5
NSAIDs
Acetaminophen	100
Opioids
Buprenorphine	5
Norbuprenorphine^a	5
Codeine	5
Dihydrocodeine	5
Fentanyl	2
Norfentanyl^a	5
Heroin	—
6-acetylmorphine^a	5
Hydrocodone	5
Hydromorphone^ab	5
Meperidine	10
Normeperidine^a	10
Methadone	10
EDDP^a	10
Morphine	5
Naloxone	10
Oxycodone	5
Oxymorphone^ab	5
Tapentadol	5
N-desmethyltapentadol^a	5
Tramadol	10
O-desmethyl-cis-tramadol^a	100
Sedative-Hypnotics
Ketamine	20
Norketamine^a	20
Stimulants
Amphetamine	10
Cocaine	10
Benzoylecgonine^a	20
Cocaethylene^a	10
Ephedrine	10
Methamphetamine	10
Methylenedioxymethamphetamine (MDMA)	10
Methylphenidate	5
Ritalinic acid^a	5
Phencyclidine (PCP)	5
Phentermine	10
Pseudoephedrine	5
^aSubstance is a metabolite of the preceding parent drug. ^bSubstance can be administered as a prescription drug.

Results

Result	Clinical Significance
Detected	One or more drug analytes were detected in the sample
Not detected	No drug analytes were detected Result does not exclude the possibility of drug use or exposure

Result

Clinical Significance

Detected

One or more drug analytes were detected in the sample

Not detected

No drug analytes were detected

Result does not exclude the possibility of drug use or exposure

Limitations

Minimum reporting limits and estimated concentrations are established for each compound, but quantitative results are not reported.
Drug concentrations must be greater than or equal to the cutoff to be reported as positive.
Drug detection depends on specimen quality and the timing of specimen collection relative to drug exposure.

References

SAMHSA - 2020 NSDUH annual national report

Substance Abuse and Mental Health Services Administration. 2020 NSDUH Annual National Report. Published Oct 2021; accessed Jul 2022.

SAMHSA - 2021 drug abuse warning network (DAWN)

Substance Abuse and Mental Health Services Administration. 2021 Drug Abuse Warning Network (DAWN) releases. Accessed Jul 2022.

Feedback